WO2026108847 - COMPOSITION AND METHOD
National phase entry is expected:
Publication Number
WO/2026/108847
Publication Date
28.05.2026
International Application No.
PCT/CN2025/136028
International Filing Date
19.11.2025
Title **
[English]
COMPOSITION AND METHOD
[French]
COMPOSITION ET PROCÉDÉ
[Chinese]
组合物及方法
Applicants **
NANJING NUTRABUILDING BIO-TECH CO., LTD.
Inventors
ZHANG, Qianjing
YAN, Ruhan
GAO, Yabing
WELLS, Shawn
LIAO, Kylin
Priority Data
PCT/CN2024/133659
22.11.2024
CN
PCT/CN2024/133663
22.11.2024
CN
PCT/CN2024/133669
22.11.2024
CN
PCT/CN2024/133675
22.11.2024
CN
PCT/CN2024/133695
22.11.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2372 | |
| EPO | Filing, Examination, Granting | 17721 | |
| Japan | Filing, Examination, Granting | 2516 | |
| South Korea | Filing, Examination, Granting | 2963 | |
| USA | Filing, Examination, Granting | 5940 |
Total:
31,512
Contact Us
Abstract[English]
A composition and a method for use in neuroprotection or improving cognitive ability, enhancing athletic performance or improving muscle function, combatting inflammation, combatting aging, extending lifespan or improving healthspan, managing stress or improving mood. The composition comprises: salidroside or a pharmaceutically acceptable salt, ester, or derivative thereof; and ergothioneine or a pharmaceutically acceptable salt, acid, ester, analog, or derivative thereof.[French]
L'invention concerne une composition et un procédé destinés à être utilisés dans la neuroprotection ou l'amélioration de la capacité cognitive, l'amélioration des performances athlétiques ou l'amélioration de la fonction musculaire, la lutte contre l'inflammation, la lutte contre le vieillissement, l'extension de la durée de vie ou l'amélioration de l'espérance de vie, la gestion du stress ou l'amélioration de l'humeur. La composition contient : du salidroside ou un sel, un ester ou un dérivé pharmaceutiquement acceptable de celui-ci ; et de l'ergothionéine ou un sel, un acide, un ester, un analogue ou un dérivé pharmaceutiquement acceptable de celle-ci.[Chinese]
用于神经保护或改善认知能力，增强运动表现或改善肌肉功能，抗炎，抗衰老，延长寿命或改善健康寿命，应激管理或改善情绪的组合物及方法，所述组合物包含红景天苷或其药学上可接受的盐、酯或衍生物；和麦角硫因或其药学上可接受的盐、酸、酯、类似物或衍生物。